The neoadjuvant chemotherapy REMAGUS 02 (RO2, ISRCTN 10059974) [3] was designed to assess anti-tumor activity of sequential epirubicin/cyclophosphamide followed by docetaxel with the randomized addition of celecoxib in HER2 negative patients or trastuzumab in HER2 positive patients [3]. This evidence concerns the gene ERBB2 and neoplasm.